CJ introduces anti-platelet therapy

Published: 2008-02-21 06:57:00

Updated: 2008-02-21 06:57:00

CJ Corporation says it has recently launched its Anplate tablets (sarpogrelate HCl), a specific antagonist for 5-HT2A, with hope of acquiring a larger share in the domestic market.

Sarpogrelate has been proven effective for the treatment of peripheral artery diseases, and its clinical potentia...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK